Sanofi pledges stable 2016 earnings despite fourth-quarter decline

Sanofi reported lower fourth-quarter earnings on Tuesday, hurt by declining sales in divisions such as diabetes, oncology and prescription drugs, but said it expected 2016 earnings per share to be stable. The French drugmaker, in the midst of a reorganization designed to address falling sales of its insulin drug Lantus, said sales of a next-generation basal insulin called Toujeo, which was launched last year in the United States, had more than doubled between the third and the fourth quarter. Sa